Recover Investment Losses: Class Action Initiated Against Replimune Group, Inc. (REPL)
Levi & Korsinsky announced a securities class action against Replimune Group on behalf of investors who purchased REPL securities between October 20, 2025 and April 10, 2026. The complaint alleges the company did not address FDA study-design concerns in its BLA and submitted data from an early unplanned analysis of RP1-104 covering only 40 patients, or 10% of the planned 400-patient enrollment.
Key figures
- Class Period
- October 20, 2025 - April 10, 2026
- Analyzed Patient Share
- 10%
- Rp1104 Analyzed Patients
- 40
- Planned Enrollment Patients
- 400
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.